What are the next steps after a PET scan showing a right upper lobe and hilar mass with local nodal metastases and moderate left hydronephrosis concerning for UPJ obstruction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of PET Scan Findings: Right Upper Lobe Mass with Nodal Metastases and Left Hydronephrosis

The next step after this PET scan should be a tissue biopsy of the right upper lobe mass via CT-guided percutaneous needle biopsy to confirm malignancy and determine histological subtype. 1

Lung Mass Management

Tissue Diagnosis

  • A pretreatment pathological diagnosis is strongly recommended before any curative treatment for the lung mass 1
  • CT-guided percutaneous lung biopsy is rated as "usually appropriate" (rating 8/9) for patients with suspected lung cancer and risk factors 1
  • Endoscopic techniques may be considered if the mass is centrally located, but the description suggests a peripheral upper lobe mass which is more amenable to percutaneous approach

Rationale for Percutaneous Approach

  • The PET scan already shows local nodal metastases, suggesting at least stage II-III disease
  • Percutaneous biopsy provides:
    • Definitive tissue diagnosis
    • Histological subtype determination (critical for treatment planning)
    • Potential for molecular testing if non-small cell lung cancer is found
    • Avoidance of more invasive surgical procedures 1

Mediastinal Staging

  • After tissue diagnosis, invasive mediastinal staging will be required to confirm the nodal involvement seen on PET
  • For patients with abnormal mediastinal lymph nodes on PET, endosonography (EBUS/EUS) is recommended over surgical staging 1
  • If EBUS/EUS is negative in the setting of high clinical suspicion, mediastinoscopy is indicated 1

Management of Left Hydronephrosis

Concurrent Urological Evaluation

  • The moderate left hydronephrosis with normal ureter requires urological consultation
  • Given the concern for UPJ obstruction, a functional study should be performed:
    • Diuretic renal scan to assess the degree of obstruction and renal function 2
    • This can be scheduled concurrently with the lung mass workup

Potential Causes to Consider

  • While primary UPJ obstruction is possible, in the context of malignancy, consider:
    • Metastatic involvement of the retroperitoneum
    • Extrinsic compression from lymphadenopathy
    • Direct tumor extension if the primary is near the kidney

Comprehensive Approach

  1. First priority: CT-guided percutaneous biopsy of the lung mass
  2. Second priority: Urological consultation with diuretic renal scan for hydronephrosis
  3. Third priority: Based on lung biopsy results:
    • If malignant: Complete staging workup including brain MRI 1
    • Invasive mediastinal staging via EBUS/EUS 1
    • Multidisciplinary tumor board discussion for treatment planning

Common Pitfalls to Avoid

  • Delaying tissue diagnosis while pursuing additional imaging
  • Assuming the hydronephrosis is unrelated to the lung mass without proper evaluation
  • Proceeding directly to surgery without adequate mediastinal staging
  • Neglecting brain MRI in the complete staging workup for lung cancer with nodal involvement

The presence of both a lung mass with nodal involvement and hydronephrosis requires a coordinated approach between thoracic oncology and urology to ensure comprehensive management of both conditions.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.